Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype-Reference-Cited by-同舟云学术

Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype

Published:2015-06 Issue:3 Volume:67 Page:442-445
ISSN:1734-1140
Container-title:Pharmacological Reports
language:en
Short-container-title:Pharmacological Reports

Author:

Bienkowski Przemyslaw,Samochowiec Jerzy^ORCID,Pelka-Wysiecka Justyna,Grzywacz Anna,Skibinska Maria,Jasiewicz Andrzej,Tybura Piotr,Wroński Michał,Jarema Marek,Samochowiec Agnieszka

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Reference20 articles.

1. The negative symptom challenge;Carpenter;Arch Gen Psychiatry,1992

2. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia;Kirkpatrick;Psychiatry Res,1989

3. Deficit schizophrenia: an update;Kirkpatrick;World Psychiatry,2008

4. Extracellular matrix molecules, their receptors, and secreted proteases in synaptic plasticity;Wlodarczyk;Dev Neurobiol,2011

5. Synaptic localization of seizure-induced matrix metalloproteinase-9 mRNA;Konopacki;Neuroscience,2007

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does the functional polymorphism-1562C/T of MMP-9 gene influence brain disorders?;Frontiers in Cellular Neuroscience;2023-05-03

2. Matrixmetalloproteinase-9 gene polymorphism (rs 17576) increases the risk of depressive symptoms in bipolar disorder;Journal of Neurosciences in Rural Practice;2022-10-22

3. Association of BDNF and MMP-9 single-nucleotide polymorphisms with the clinical phenotype of schizophrenia;Frontiers in Psychiatry;2022-10-17

4. The tetrapartite synapse in neuropsychiatric disorders: Matrix metalloproteinases (MMPs) as promising targets for treatment and rational drug design;Biochimie;2022-10

5. Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020);Expert Opinion on Therapeutic Patents;2021-02-22